Equity Overview
Price & Market Data
Price: $8.71
Daily Change: +$0.37 / 4.25%
Daily Range: $8.65 - $8.71
Market Cap: $1,815,549,440
Daily Volume: 491
Performance Metrics
1 Week: 12.70%
1 Month: -18.79%
3 Months: -27.79%
6 Months: -26.91%
1 Year: 32.38%
YTD: -31.30%
Company Details
Employees: 325
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.